Virax Biolabs Group Limited (VRAX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -2.92M | -2.45M | -1.92M | -2.79M | -3.46M | -1.88M | -2.3M | -530.38K | -278.68K | -170.73K | -186.15K |
| Operating CF Margin % | -181803.23% | -178134.4% | -38736.6% | -3490.23% | -4519.82% | -67235.56% | -39869.77% | 571.13% | - | -155.46% | -745.54% |
| Operating CF Growth % | -52.37% | 12% | 44.51% | -48.11% | -50.56% | -255.08% | -724.05% | -210.66% | - | 8.29% | - |
| Net Income | -2.34M | -3.3M | -2.76M | -3.82M | -2.91M | -4.01M | -1.44M | -1.16M | -552.42K | -307.53K | -184.87K |
| Depreciation & Amortization | 216.7K | 185.2K | 158.19K | 85.38K | 17.72K | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 591.31K | 38.98K | 925.7K | 86.27K | 1.51M | 248.98K | 290.36K | 287.44K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | -378.84K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -177.86K | 181.25K | 374.24K | -58.79K | 312.65K | 865.12K | 607.93K | -650.26K | 263.43K | -35.63K | 22.92K |
| Working Capital Changes | -623.46K | -107.63K | 266.39K | 82.23K | -585.82K | 875.42K | -1.09M | 644.38K | 12 | 86.22K | -24.2K |
| Change in Receivables | -145.04K | 2.36K | -2.36K | -34.48K | -183.36K | 0 | 0 | 1.62K | 928 | 7.91K | 0 |
| Change in Inventory | 40.49K | 30.58K | -64.87K | -35.88K | -24.51K | 0 | 20.95K | 121 | 0 | 67.91K | 0 |
| Change in Payables | -146.65K | 0 | 0 | -522.99K | -49.26K | 390.08K | -390.08K | 631.79K | 9.36K | 10.4K | 0 |
| Cash from Investing | -141.5K | -355.89K | -248K | -456.27K | -708.18K | -178.4K | 0 | -24.66K | 0 | 0 | -245 |
| Capital Expenditures | -141.5K | -355.89K | -248K | -459.92K | -708.18K | -178.4K | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 8800.06% | 25826.92% | 5006.97% | 575.48% | 925.73% | 6369.26% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 3.65K | -215.6K | -178.4K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.18M | -246.46K | 5.86M | 1.73M | -78.81K | 6.84M | 6.84M | 540.47K | 272.74K | 123.23K | 176.16K |
| Debt Issued (Net) | 163.11K | -190.26K | -51.55K | -3.66K | -146.25K | 146.25K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 2.07M | 0 | 5.91M | -85.5K | 0 | 7.1M | 0 | 419.61K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -85.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -52.39K | -56.2K | 0 | 1.82M | 67.44K | -398.95K | 6.84M | 120.85K | 272.74K | 123.23K | 176.16K |
| Net Change in Cash | -883.48K | -3.06M | 3.7M | -1.52M | -4.24M | 4.78M | 4.55M | 10.08K | -5.95K | -47.5K | -9.99K |
| Free Cash Flow | -3.06M | -3M | -2.17M | -3.25M | -4.17M | -2.06M | -2.3M | -530.38K | -278.68K | -170.73K | -186.15K |
| FCF Margin % | -190603.23% | -217768.29% | -43743.57% | -4065.71% | -5445.55% | -73604.82% | -39869.77% | 571.13% | - | -155.46% | -745.54% |
| FCF Growth % | -41.46% | 7.65% | 47.99% | -57.6% | -81.4% | -288.71% | -724.05% | -210.66% | - | 8.29% | - |
| FCF per Share | -0.64 | -0.69 | -0.70 | -1.45 | -2.35 | -1.33 | -1.97 | -0.47 | -0.25 | -0.15 | -0.02 |
| FCF Conversion (FCF/Net Income) | 1.25x | 0.74x | 0.70x | 0.73x | 1.19x | 0.47x | 1.59x | 0.46x | 0.50x | 0.56x | 1.05x |
| Interest Paid | 0 | 0 | 5.79K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |